深田 淳一 (フカダ ジュンイチ)

Fukada, Junichi

写真a

所属(所属キャンパス)

医学部 放射線科学教室(治療) (信濃町)

職名

専任講師

外部リンク

経歴 【 表示 / 非表示

  • 1999年05月
    -
    2001年04月

    慶應義塾大学医学部, 放射線科, 研修医

  • 2001年05月
    -
    2002年05月

    慶應義塾大学医学部, 放射線科, 助手(専修医)

  • 2002年06月
    -
    2002年09月

    慶應義塾大学医学部, 放射線科, 助手

  • 2002年10月
    -
    2004年10月

    国立病院東京医療センター, 放射線科, レジデント

  • 2004年11月
    -
    2007年03月

    慶應義塾大学医学部, 放射線科, 助手

全件表示 >>

学歴 【 表示 / 非表示

  • 1999年03月

    慶應義塾大学, 医学部

    卒業

学位 【 表示 / 非表示

  • 博士(医学), 慶應義塾大学, 2012年12月

 

論文 【 表示 / 非表示

  • Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline resectable pancreatic cancer: A long-term follow-up study

    Endo Y., Kitago M., Aiura K., Shinoda M., Yagi H., Abe Y., Oshima G., Hori S., Nakano Y., Itano O., Fukada J., Masugi Y., Kitagawa Y.

    World Journal of Surgical Oncology (World Journal of Surgical Oncology)  17 ( 1 )  2019年08月

     概要を見る

    © 2019 The Author(s). Background: We aimed to evaluate the efficacy and safety of 5-fluorouracil-based neoadjuvant chemoradiotherapy (NACRT) in patients with resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC). Methods: This retrospective study investigated the clinicopathological features and > 5-year survival of patients with T3/T4 PDAC who underwent NACRT at our institute between 2003 and 2012. Results: Seventeen resectable and eight borderline resectable patients were included. The protocol treatment completion and resection rates were 92.0% and 68.0%, respectively. Two patients failed to complete chemotherapy owing to cholangitis or anorexia. Common grade 3 toxicities included anorexia (12%), neutropenia (4%), thrombocytopenia (4%), anemia (4%), and leukopenia (12%). Pathologically negative margins were achieved in 94.1% of patients who underwent pancreatectomy. Pathological response according to Evans' classification was grade IIA in 10 patients (58.8%), IIB in 5 patients (29.4%), and IV in 2 patients (11.8%). Postoperative pancreatic fistulas were observed in four patients (23.5%), delayed gastric emptying in one patient (5.9%), and other operative morbidities in four patients (23.5%). The 1-, 2-, 5-, and 10-year overall survival rates were 73.9%, 60.9%, 60.9%, and 39.1%, respectively (median follow-up period, 80.3 months). Conclusions: NACRT is tolerable and beneficial for resectable/borderline resectable PDAC, even in the long-term.

  • A Highly Advanced Gastric Cancer Maintaining a Clinical Complete Response after Chemoradiotherapy Comprising S-1 and Cisplatin

    Yura M., Takahashi T., Fukuda K., Nakamura R., Wada N., Fukada J., Kawakubo H., Takeuchi H., Shigematsu N., Kitagawa Y.

    Case Reports in Gastroenterology (Case Reports in Gastroenterology)  12 ( 3 ) 578 - 585 2018年09月

     概要を見る

    © 2018 The Author(s). Published by S. Karger AG, Basel. We report a patient with highly advanced gastric carcinoma who was treated successfully with chemoradiotherapy (CRT) comprising S-1 and cisplatin. The patient was a 71-year-old male who was diagnosed with advanced gastric carcinoma by esophagogastroduodenoscopy (EGD) by medical examination. EGD demonstrated type 3 advanced gastric carcinoma in the posterior wall of the upper gastric body. An abdominal computed tomography (CT) scan showed that the gastric wall was thickened due to gastric primary tumor, and large lymph nodes (LNs) including the lesser curvature LN, anterosuperior LN along the common hepatic artery and some para-aortic LNs were detected. The patient was diagnosed with stage IV advanced gastric carcinoma according to the Japanese classification of gastric carcinoma (cT4a, cN3, cM1 [para-aortic LN], cStage IV). Preoperative CRT was carried out in an attempt to downstage the disease. Remarkable reduction of the primary tumor and metastatic LNs was observed after initial CRT, and radiological examination determined that a partial response had been achieved. Adverse effects included grade 2 anorexia and grade 3 ALP elevation (919 U/ml). No grade 4 or more severe adverse event was observed. After CRT, although we recommended curative surgery, the patient refused surgical treatment and opted for conservative treatment. Thus, we continued S-1 oral administration for 1 year. Five months after beginning CRT, upper endoscopy showed that the tumor had maintained regression and scar formation, in which no cancer cells were detected by endoscopic biopsy. The patient is doing well and has maintained a clinical complete response for more than 42 months without curative surgery. CRT could be considered as an option for treatment of patients with locally advanced gastric carcinoma diagnosed as unresectable, or for those who refuse surgical treatment.

  • Fatal Intracranial Hemorrhage Due to Thrombocytopenia in a Patient with Castration-Resistant Prostate Cancer Showing Extensive Bone Uptake of Injected 223Ra Dichloride

    深田 淳一

    Clinical Nuclear Medicine (Clinical Nuclear Medicine)  43 ( 7 ) 546 - 547 2018年07月

    研究論文(学術雑誌),  ISSN  0363-9762

     概要を見る

    © 2018 Wolters Kluwer Health, Inc. All rights reserved. A 64-year-old man with castration-resistant prostate cancer received 223Ra injection to treat bone metastases. The patient underwent a 223Ra SPECT scan after the first 223Ra injection in which there was increased uptake all over the spine. Spine-to-background activity ratio in the patient was approximately three times greater than normal spine-to-background activity ratios in 223Ra SPECT obtained from the other patients. Eight days after the fifth injection, the patient exhibited a very poor neurologic examination and died of intracranial hemorrhage due to severe thrombocytopenia (platelet counts, 23,000/mm3). The extensive radiation to the spine may have enhanced myelophthisic process in this case.

  • Long-term results of concurrent chemoradiotherapy with daily-low-dose continuous infusion of 5-fluorouracil and cisplatin (LDFP) for Stage I-II esophageal carcinoma

    深田 淳一

    Diseases of the Esophagus (Diseases of the Esophagus)  31 ( 4 ) 546 - 547 2018年04月

    研究論文(学術雑誌),  ISSN  1442-2050

     概要を見る

    © The Author(s) 2017. Published by Oxford University Press on behalf of International Society for Diseases of the Esophagus. All rights reserved. We investigated long-term treatment outcomes and the feasibility of chemoradiotherapy consisting of daily-low-dose 5-fluorouracil and cisplatin (LDFP) chemotherapy plus radiotherapy for Stage I-II squamous cell esophageal cancer. Treatment records from the 2000 through 2008 period were reviewed retrospectively. Fractionated radiotherapy was performed with a total dose of 60 Gy delivered in 2 Gy per fraction. LDFP chemotherapy, as continuous infusion of 200 mg/m 2 5-fluorouracil combined with one hour infusion of 4 mg/m 2 cisplatin, was administered on the same days as radiotherapy. Survival was calculated by the Kaplan-Meier method. Survival, responses, failure patterns, and toxicities were evaluated. Seventy-six (47 stage I and 29 stage II) patients were analyzed with a median follow-up of 93.6 months. The 8-year overall survival (OS), progression-free survival (PFS) and cause-specific survival (CSS) rates were 63.4%, 49.8%, and 76.7%, respectively. The 8-year OS, PFS, and CSS for stage I and stage II patients were 71.0%/56.1%/82.9% and 45.2%/40.2%/66.6%, respectively. Sixty-eight patients (89.5%) completed the treatment regimen. A complete response (CR) was achieved in 68 patients (89.5%). Twenty-five patients (36.8%) experienced recurrence after CR. The failure patterns were (overlap included): local failure (n = 12), nodal metastasis (n = 12), distant metastasis (n = 3), details unknown (n = 2). Salvage therapy was performed for local failure; endoscopic therapy (n = 7) or surgery (n = 2). Six patients remain alive without relapse after salvage endoscopic therapy. Major Grade 3 or higher acute adverse events were leukopenia (22%), anorexia (17%), and esophagitis (11%). Major late toxicities (Grade 3 or 4) involved pericardial effusion (12%), pleural effusion (4%), and esophageal stenosis (3%). Chemoradiotherapy with LDFP provided favorable long-term survival with acceptable toxicity for Stage I-II squamous cell esophageal cancer. The tumor response was excellent, but close endoscopic follow-up is essential for detecting and treating local recurrence.

  • Synovial sarcoma of the maxillary sinus: An extremely rare case with excellent response to chemotherapy

    深田 淳一

    OncoTargets and Therapy (OncoTargets and Therapy)  11   483 - 488 2018年

    研究論文(学術雑誌),  ISSN  1178-6930

     概要を見る

    © 2018 Saito et al. This paper presents an extremely rare case of synovial sarcoma arising from the maxillary sinus, which resulted in a clinically complete response to chemotherapy. Synovial sarcoma is a rare soft tissue malignant tumor, most commonly affecting the extremities. While ∼10% occur in the head and neck region, synovial sarcoma of the sinonasal tract is extremely rare, with only 11 cases having been reported previously. As with other sarcomas, the standard treatment is complete resection while allowing for a safe margin, but this is often difficult in the head and neck area due to the complicated anatomy there. This makes the treat­ment of head and neck sarcoma challenging and leads to the need for a multimodal approach in advanced cases. However, the exact efficacy of chemotherapy is not well understood. In this report, we present a case of unresectable maxillary sinus synovial sarcoma that was success­fully treated by chemotherapy followed by radiation therapy. A 53-year-old Japanese man was referred to our hospital with a history of left nose obstruction over the previous couple of years. Computed tomography/magnetic resonance imaging revealed a tumor arising from the maxillary sinus that extended to adjacent tissues. A biopsy was performed, and the tumor was diagnosed as synovial sarcoma. Since the tumor was unresectable, neoadjuvant chemotherapy was administered. The response was excellent, and the tumor became undetectable under endoscopy and radiological imaging. This provided us with a clinical evaluation of “complete response”. The treatment was concluded with definitive radiotherapy and two more cycles of adjuvant chemotherapy. The patient remains free of disease 12 months after treatment. Synovial sarcoma of the head and neck is a rare entity; complete resection is the treatment of choice but (neo)adjuvant chemotherapy can be considered in unresectable cases, as we show here in the present case.

全件表示 >>

KOARA(リポジトリ)収録論文等 【 表示 / 非表示

全件表示 >>

研究発表 【 表示 / 非表示

  • Evaluation of our modified tangential irradiation technique for breast cancer patients using dose volume histogram (DVH)

    Takeda A, Shigematsu N, Kawaguchi O, Kutsuki S, Ishibashi R, Kunieda E, Takeda T, Takemasa K, Ito H, Ohashi T, Fukada J, Yamamoto A, Kubo A

    Scientific Assembly and Anual Meeting of RSNA, 

    2002年12月

    ポスター発表

  • Micro multileaf collimator(MMLC)によるRadiosurgery施行時の幾何学的精度測定

    国枝悦夫,川口修,川瀬貴嗣,深田淳一,茂松直之,久保敦司,瀬黒清一,北川五十雄

    日本放射線腫瘍学会第15回学術大会, 

    2002年11月

    口頭発表(一般)

  • 聴神経腫瘍の定位放射線照射における分割照射の優位性

    川瀬貴嗣,国枝悦夫,川口修,茂松直之,沓木章二,深田淳一,久保敦司

    日本放射線腫瘍学会第15回学術大会, 

    2002年11月

    口頭発表(一般)

  • Micro-multileaf Collimator(MMLC)によるradiosurgery

    国枝悦夫,川口修,大平貴之,小野塚聡,茂松直之,深田淳一,武田篤也,久保敦司

    第11回日本定位放射線治療学会, 

    2002年07月

    口頭発表(一般)

  • Dynamic IA-CT angioとMicro-multileaf CollimatorによるAVMのradiosurgery

    国枝悦夫,川口修,深田淳一,茂松直之,久保敦司

    日本放射線学会関東地方会, 

    2002年06月

    口頭発表(一般)

全件表示 >>

競争的研究費の研究課題 【 表示 / 非表示

  • 低線量照射における放射線超感受性を用いた低侵襲がん治療戦略の開発-膠芽腫での検討

    2017年04月
    -
    2020年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 深田 淳一, 基盤研究(C), 補助金,  研究代表者

  • 膠芽腫に対する新たな治療戦略の開発-低線量放射線高感受性に関する基礎的検討

    2014年04月
    -
    2017年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 深田 淳一, 基盤研究(C), 補助金,  研究代表者

     研究概要を見る

    膠芽腫は最も難治性の中枢神経原発悪性腫瘍である。低線量照射に対する細胞反応は放射線高感受性であることに着目し、基礎的検討を行った。膠芽腫細胞株に対して低線量照射を行い、細胞生存率と細胞周期、アポトーシス誘導を測定した。コロニー形成法による検討では、放射線超感受性を示唆する生存曲線が複数のセルラインで観察された。細胞周期やアポトーシス誘導の変化は検出困難であった。そこで低線量照射を反復して行ったところ、照射間隔が比較的長い(30分)群で細胞生存率の低下が観察され、照射後早期(30分)でG1期分画比率の減少とG2/M期分画の増加、アポトーシス分画の比率の増加が観察され、有効な治療法と考えられた。

受賞 【 表示 / 非表示

  • 日本放射線腫瘍学会梅垣賞

    2014年12月

 

担当授業科目 【 表示 / 非表示

  • 放射線医学講義

    2022年度

  • 放射線医学講義

    2021年度

  • 放射線医学講義

    2020年度

  • 放射線医学講義

    2019年度

担当経験のある授業科目 【 表示 / 非表示

  • 臨床実習 放射線科学

    慶應義塾

    2015年04月
    -
    2016年03月

  • 系統講義 放射線医学「治療」放射線治療・各論

    慶應義塾

    2015年04月
    -
    2016年03月

    講義

  • 自主学習

    慶應義塾

    2015年04月
    -
    2016年03月

    実習・実験